GenVec president and ceo to retire

US firm hires recruitment firm to find a successor

GenVec, a US biopharmaceutical company that uses differentiated, proprietary technologies to create therapeutics and vaccines, says Paul Fischer plans to retire as president and chief executive. Dr Fischer will continue in the role until a successor is named and the ceo transition is complete. The Board will use Spencer Stuart, an executive search firm, to advise it on potential candidates.

Fischer has been with the Gathersburg, MD firm for 15 years.

You may also like

Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Pharmaceutical

New research suggests repurposed diabetic drug may help prostate cancer

A class of medication called SGLT2 inhibitors, traditionally used for diabetes, may help slow prostate cancer progression in men receiving hormone treatment
Drug Delivery

Indonesia looks to oral GLP-1s as it battles rising obesity

Novo Nordisk's oral GLP-1 therapy for chronic weight management could help the country deliver injectable-comparable weight loss alongside cardiovascular risk-reduction benefits for its expanding population
Pharmaceutical

Astoriom acquires Precision Stability Storage, expanding sample management capabilities

The acquisition strengthens Astoriom’s stability storage capabilities to meet increasing demand across North America and offers reliable, compliant and accessible solutions to advance scientific discovery and product development
Manufacturing

Key factors in engineering a perfect vacuum drying cycle – from agitator stroke to cake height

Pharmaceuticals demand exceptional control at every stage of production to maintain product integrity and maximise recovery. Drying is particularly critical, as it determines how much material is recovered and whether key attributes like stability, crystal form, and residual solvent content remain within specification
Pharmaceutical

Novo Nordisk launches the first oral GLP-1 in the US with new Wegovy pill

The new formulation of the obesity drug places Novo a step ahead of its competitor, Eli Lilly, whose rival drug orforglipron is still being assessed by regulators
Subscribe now